| Primary |
| Drug Use For Unknown Indication |
32.5% |
| Breast Cancer |
10.8% |
| Diffuse Large B-cell Lymphoma |
7.3% |
| Product Used For Unknown Indication |
7.3% |
| Non-hodgkin's Lymphoma |
7.2% |
| B-cell Lymphoma |
6.0% |
| Acute Lymphocytic Leukaemia |
3.7% |
| Chronic Lymphocytic Leukaemia |
3.6% |
| Plasma Cell Myeloma |
2.8% |
| Lymphoma |
2.7% |
| Burkitt's Lymphoma |
2.6% |
| Peripheral T-cell Lymphoma Unspecified |
2.1% |
| Multiple Myeloma |
1.8% |
| Prophylaxis |
1.8% |
| Systemic Lupus Erythematosus |
1.5% |
| Bone Marrow Conditioning Regimen |
1.4% |
| Haematological Malignancy |
1.3% |
| Premedication |
1.2% |
| Hypertension |
1.1% |
| Primary Mediastinal Large B-cell Lymphoma |
1.1% |
|
| Vomiting |
9.4% |
| Sepsis |
9.1% |
| Pyrexia |
8.7% |
| Disease Progression |
7.7% |
| Thrombocytopenia |
7.3% |
| Septic Shock |
7.0% |
| Neutropenia |
6.6% |
| Cytomegalovirus Infection |
4.2% |
| Pneumonia |
4.2% |
| Pulmonary Embolism |
4.2% |
| Tachycardia |
4.2% |
| Stomatitis |
3.8% |
| Second Primary Malignancy |
3.5% |
| Bone Sarcoma |
3.1% |
| Ovarian Failure |
3.1% |
| Progressive Multifocal Leukoencephalopathy |
3.1% |
| Toxicity To Various Agents |
2.8% |
| White Blood Cell Count Decreased |
2.8% |
| Haematological Malignancy |
2.4% |
| Infection |
2.4% |
|
| Secondary |
| Drug Use For Unknown Indication |
25.6% |
| Diffuse Large B-cell Lymphoma |
9.1% |
| Product Used For Unknown Indication |
8.3% |
| B-cell Lymphoma |
8.1% |
| Breast Cancer |
6.3% |
| Non-hodgkin's Lymphoma |
5.8% |
| Prophylaxis |
4.5% |
| Prophylaxis Of Nausea And Vomiting |
3.7% |
| Acute Lymphocytic Leukaemia |
3.4% |
| Lymphoma |
3.3% |
| Epidural Anaesthesia |
3.1% |
| Chronic Lymphocytic Leukaemia |
2.8% |
| Systemic Lupus Erythematosus |
2.7% |
| Premedication |
2.6% |
| Off Label Use |
2.4% |
| Peripheral T-cell Lymphoma Unspecified |
2.3% |
| Multiple Sclerosis |
2.0% |
| Multiple Myeloma |
1.6% |
| Hypertension |
1.3% |
| Infection Prophylaxis |
1.2% |
|
| Vomiting |
15.5% |
| White Blood Cell Count Decreased |
11.2% |
| Septic Shock |
7.8% |
| Neutropenia |
6.9% |
| Thrombocytopenia |
6.0% |
| Hypotension |
4.3% |
| Progressive Multifocal Leukoencephalopathy |
4.3% |
| Sneezing |
4.3% |
| Staphylococcal Infection |
4.3% |
| Troponin T Increased |
4.3% |
| Pneumonia |
3.4% |
| Pneumonitis |
3.4% |
| Psychotic Disorder |
3.4% |
| Renal Impairment |
3.4% |
| Sepsis |
3.4% |
| Toxicity To Various Agents |
3.4% |
| Dyspnoea |
2.6% |
| Guillain-barre Syndrome |
2.6% |
| Hepatic Function Abnormal |
2.6% |
| Hypoaesthesia |
2.6% |
|
| Concomitant |
| Non-hodgkin's Lymphoma |
30.3% |
| Breast Cancer Recurrent |
15.2% |
| Breast Cancer |
9.1% |
| Hodgkin's Disease |
9.1% |
| Premedication |
9.1% |
| Hypertension |
6.1% |
| Osteoporosis Prophylaxis |
6.1% |
| Systemic Sclerosis |
6.1% |
| Lymphoma |
3.0% |
| Prophylaxis Against Gastrointestinal Ulcer |
3.0% |
| Prophylaxis Of Nausea And Vomiting |
3.0% |
|
| Interstitial Lung Disease |
28.6% |
| Hepatotoxicity |
14.3% |
| Infection |
14.3% |
| Pubis Fracture |
14.3% |
| Self Injurious Behaviour |
14.3% |
| Stomatitis |
14.3% |
|
| Interacting |
| Hypertension |
33.3% |
| Glomerulonephritis |
20.0% |
| Erysipelas |
13.3% |
| Hyperlipidaemia |
6.7% |
| Metabolic Acidosis |
6.7% |
| Oedema Peripheral |
6.7% |
| Prophylaxis Against Gastrointestinal Ulcer |
6.7% |
| Renal Impairment |
6.7% |
|
|
